Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
NCT06621602 · View on ClinicalTrials.gov ↗
Study Summary
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Conditions Studied
Study Locations (18)
California
- Parkinson's Research Centers of America - Orange County — Aliso Viejo
- Cedars Sinai — Los Angeles
- Parkinson's Research Centers of America - Palo Alto — Palo Alto
Arizona
- CND Life Sciences — Scottsdale
- Movement Disorders Center of Arizona — Scottsdale
Florida
- Aventura Neurologic Associates, LLC — Aventura
- Parkinson's Disease and Movement Disorders Center - Boca Raton — Boca Raton
New York
- Parkinson's Research Centers of America - Long Island — Commack
- University of Rochester — Rochester
Colorado
- University of Colorado — Aurora
Georgia
- Atlanta NeuroScience Institute ANI — Atlanta
Kansas
- Parkinson's Disease and Movement Disorders Center at KUMC — Kansas City
Kentucky
- Neurology Multidisciplinary Clinic at Norton Healthcare — Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2027-04 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06621602
The ClinicalTrials.gov registry entry for NCT06621602 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CND Life Sciences, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06621602 reports 18 study locations spanning 13 distinct geographic areas — top geographies include California, Arizona, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06621602 about?
NCT06621602 is a clinical study titled "Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease". This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN q...
What is the current status of trial NCT06621602?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2024-12-17. Estimated completion is 2027-04.
What conditions does trial NCT06621602 study?
This clinical trial studies the following conditions: Parkinson Disease, REM Behavior Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06621602?
This trial is sponsored by CND Life Sciences, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06621602 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.